Quest Diagnostics stock faces a July 2027 leadership change
Published on 10/08/2026 at 06:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics stock (ISIN US74834L1008) was last at USD 227 on the NYSE on October 7, 2026, at 4:00 p.m. ET, down 0.61 percent from USD 228.39. The company announced on October 6 that Catherine T. Doherty will retire in July 2027, making the leadership transition the latest company-specific issue for shareholders.
Leadership transition starts November 1
According to GuruFocus on October 6, 2026, Doherty will become executive vice president on November 1 while retaining oversight of health systems, the Corewell Health joint venture and Project Nova. Her annual base salary remains USD 650,000, and the approved restricted stock unit award has a target value of USD 1.2 million.
The change extends the management timeline rather than creating an immediate vacancy. Doherty's retirement is scheduled for July 2027, while Project Nova is intended to modernize Quest's order-to-cash processes and related technology infrastructure.
Q2 revenue rose 10.2 percent
Quest's Q2 2026 results provide the operating backdrop. Fortune reports that revenue increased 10.2 percent year over year to USD 3.04 billion, while adjusted EPS rose to USD 3.12 from USD 2.62.
The adjusted EPS comparison includes a USD 0.10 benefit from the favorable resolution of tax contingencies, according to Fortune. Quest also raised its full-year 2026 revenue guidance to USD 11.95 billion to USD 12.05 billion and adjusted EPS guidance to USD 11.05 to USD 11.25.
Analysts see limited upside
MarketBeat lists a Moderate Buy consensus from 13 analysts, with an average price target of USD 237.85, a high of USD 260 and a low of USD 200. The average target lies 4.8 percent above the USD 227 reference price.
Yahoo Finance shows Barclays maintaining an Overweight rating on October 7, 2026, while raising its target from USD 250 to USD 260. That target sits above the broader consensus average, but the stock remains below its yearly high.
October 22 is the next checkpoint
MarketBeat lists October 22, 2026, before the market opens for Quest's Q3 results. The date gives investors a near-term test of whether the Q2 growth rate and the raised full-year outlook are carrying into the second half.
Stock stays below the yearly high
At USD 227 on the NYSE on October 7, 2026, Quest Diagnostics stock stood USD 21.84 below its 52-week high of USD 248.84 and above its low of USD 171.18.
Quest Diagnostics stock facts
- Company: Quest Diagnostics Incorporated
- ISIN: US74834L1008
- Ticker: DGX
- Trading venue: NYSE
- Price (as of October 7, 2026, 4:00 p.m. ET): USD 227
- Market capitalization: USD 25.1 billion (as of October 7, 2026)
- 52-week range: USD 171.18-248.84 (as of October 7, 2026)
- Sector / Industry: Health Care / Healthcare Providers and Services
Upcoming dates for Quest Diagnostics stock
- October 22, 2026: Q3 2026 results before the market opens
